Compounding alliance publishes peptide policy page with FDA enforcement memo
The Alliance for Pharmacy Compounding collected its issue brief, PCAC recommendation letter and FDA memo on peptides in one advocacy page.
DO
By Daniel Okafor · Regulatory Correspondent
Oct 2 09:53 ETSource: Alliance for Pharmacy Compounding
The wire
- 01APC launched a4pc.org/peptides carrying its peptide issue brief, its recommendation letter to the Pharmacy Compounding Advisory Committee and a memo to FDA on enforcement authority, plus a companion page on desiccated thyroid extract.
- 02Compounders and 503A operators now have APC's stated policy position on peptides in one place as the FDA category debate continues.
- 03The pages are advocacy documents, not regulatory decisions; FDA has not acted on the recommendations described.
From the source
Read at a4pc.orgNew a4pc.org landing pages: Peptides, DTE
APC has published two new pages on a4pc.org that spell out our policy recommendations on peptides and on desiccated thyroid extract (DTE). Together, they give members a clear statement of where APC stands on two closely watched issues in compounding. Here’s what you’ll find on each page.
